Logo

Codon Devices to Develop Therapeutic Proteins for Merrimack

Apr 16, 2008
NEW YORK (GenomeWeb News) – Codon Devices will work with Merrimack Pharmaceuticals to develop therapeutic proteins under a research, development, and license agreement, Codon said today.
 
Codon will use its BioLogic platform to engineer proteins for specifications set by Merrimack, which is developing therapeutic products aimed at autoimmune disease and cancer.
 
Merrimack will pay Codon clinical milestone payments and royalties on net sales of any protein products that may result from the agreement.

Breaking News
The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.